GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (OTCPK:BGLAF) » Definitions » Cyclically Adjusted PS Ratio

BioGaia AB (BioGaia AB) Cyclically Adjusted PS Ratio : 15.58 (As of Jun. 03, 2024)


View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB Cyclically Adjusted PS Ratio?

As of today (2024-06-03), BioGaia AB's current share price is $12.31. BioGaia AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.79. BioGaia AB's Cyclically Adjusted PS Ratio for today is 15.58.

The historical rank and industry rank for BioGaia AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

BGLAF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 9.41   Med: 13.34   Max: 18.84
Current: 12.88

During the past years, BioGaia AB's highest Cyclically Adjusted PS Ratio was 18.84. The lowest was 9.41. And the median was 13.34.

BGLAF's Cyclically Adjusted PS Ratio is ranked worse than
95.3% of 745 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs BGLAF: 12.88

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioGaia AB's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.352. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.79 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


BioGaia AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for BioGaia AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB Cyclically Adjusted PS Ratio Chart

BioGaia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.56 15.71 13.85 9.70 10.30

BioGaia AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.29 12.53 10.56 10.30 12.59

Competitive Comparison of BioGaia AB's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Cyclically Adjusted PS Ratio falls into.



BioGaia AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BioGaia AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=12.31/0.79
=15.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, BioGaia AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.352/132.2054*132.2054
=0.352

Current CPI (Mar. 2024) = 132.2054.

BioGaia AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.160 100.432 0.211
201409 0.129 100.161 0.170
201412 0.184 100.225 0.243
201503 0.188 99.950 0.249
201506 0.187 99.995 0.247
201509 0.146 100.228 0.193
201512 0.141 100.276 0.186
201603 0.185 100.751 0.243
201606 0.189 101.019 0.247
201609 0.170 101.138 0.222
201612 0.174 102.022 0.225
201703 0.182 102.022 0.236
201706 0.207 102.752 0.266
201709 0.213 103.279 0.273
201712 0.234 103.793 0.298
201803 0.219 103.962 0.278
201806 0.234 104.875 0.295
201809 0.226 105.679 0.283
201812 0.311 105.912 0.388
201903 0.213 105.886 0.266
201906 0.272 106.742 0.337
201909 0.198 107.214 0.244
201912 0.246 107.766 0.302
202003 0.214 106.563 0.265
202006 0.301 107.498 0.370
202009 0.170 107.635 0.209
202012 0.236 108.296 0.288
202103 0.234 108.360 0.285
202106 0.239 108.928 0.290
202109 0.198 110.338 0.237
202112 0.225 112.486 0.264
202203 0.294 114.825 0.339
202206 0.284 118.384 0.317
202209 0.234 122.296 0.253
202212 0.262 126.365 0.274
202303 0.346 127.042 0.360
202306 0.290 129.407 0.296
202309 0.284 130.224 0.288
202312 0.287 131.912 0.288
202403 0.352 132.205 0.352

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioGaia AB  (OTCPK:BGLAF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BioGaia AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioGaia AB (BioGaia AB) Business Description

Traded in Other Exchanges
Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.